Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy
Conditions
Epilepsy
Trial Timeline
Jan 23, 2018 → Jun 25, 2020
NCT ID
NCT03428360About Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category is a phase 3 stage product being developed by Aquestive Therapeutics for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT03428360. Target conditions include Epilepsy.
What happened to similar drugs?
20 of 20 similar drugs in Epilepsy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03428360 | Phase 3 | Completed |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 35 |
| Lacosamide | UCB | Phase 3 | 40 |
| Zonisamide + Placebo | Eisai | Phase 3 | 32 |
| Zonegran | Eisai | Approved | 35 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| perampanel | Eisai | Approved | 35 |
| E2007 + Placebo | Eisai | Phase 2 | 35 |
| Placebo + Rufinamide | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| Perampanel Oral Tablet | Eisai | Approved | 43 |
| perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Approved | 43 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| Perampanel | Eisai | Phase 2 | 35 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 43 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 35 |